The National Cancer Institute (NCI) initially suspended the enrollment of patients in the Treatment Referral Center Protocol of Bevacizumab (Avastinâ„¢) for Metastatic Colorectal Cancer on October 31, 2003, because the study had reached its initial accrual goal. Per the study protocol, enrollment was suspended until sufficient evidence of anti-tumor activity was demonstrated or bevacziumab became […]

A study funded by the National Cancer Institute, part of the National Institutes of Health, shows for the first time that microarray data generated in different laboratories can produce highly comparable results. For this comparison study, appearing in the Jan. 15, 2005, Clinical Cancer Research*, four separate laboratories analyzed gene expression (whether genes are turned […]

Twelve consumer advocates have taken seats as new members on the National Cancer Institute (NCI) Director’s Consumer Liaison Group (DCLG), joining three returning members, as the NCI increases its initiatives to reach out to the cancer community.